Erythropoietin use and abuse

Erythropoietin use and abuse

Recombinant human erythropoietin (rhEPO) is arguably the most successful therapeutic application of recombinant DNA technology till date. It was isolated in 1977 and the gene decoded in 1985. Since then, it has found varied applications, especially in stimulating erythropoiesis in anemia due to chro...

Full description

Bibliographic Details
Main Authors:	M Joseph John, Vineeth Jaison, Kunal Jain, Naveen Kakkar, Jubbin J Jacob
Format:	Article
Language:	English
Published:	Wolters Kluwer Medknow Publications 2012-01-01
Series:	Indian Journal of Endocrinology and Metabolism
Subjects:	Abuse continuous erythropoietin receptor activator darbepoetin erythropoietin
Online Access:	http://www.ijem.in/article.asp?issn=2230-8210;year=2012;volume=16;issue=2;spage=220;epage=227;aulast=John

Similar Items

SEARCH OF NEW PHARMACEUTICALS ON THE BASIS OF DARBEPOETIN IN THE TREATMENT OF ISCHEMIC STROKE (REVIEW OF LITERATURE)
by: Konstantin Reznikov, et al.
Published: (2017-03-01)

Efficacy of erythropoietin as a neuroprotective agent in CKD-associated cognitive dysfunction: A literature systematic review
by: Michelangela Barbieri, et al.
Published: (2024-05-01)

Upregulation of erythropoietin and erythropoietin receptor in castration-resistant progression of prostate cancer
by: Chen Ye, et al.
Published: (2020-01-01)

STAT5 as a Key Protein of Erythropoietin Signalization
by: Zuzana Tóthová, et al.
Published: (2021-07-01)

New alternatives for erythropoietin therapy in chronic renal failure
by: Stoian Irina, et al.
Published: (2007-12-01)

Randomized Study of Darbepoetin Alfa and Recombinant Human Erythropoietin for Treatment of Renal Anemia in Chronic Renal Failure Patients Receiving Peritoneal Dialysis
by: Wen-Yi Li, et al.
Published: (2008-11-01)

THE STUDY OF RENOPROTECTIVE PROPERTIES OF ERYTROPOETIN DERIVATIVES ON THE KIDNEY ISCHEMIA-REPERFUSION MODEL
by: V. V. Elagin, et al.
Published: (2018-12-01)

Darbepoetin Use for the Treatment of Anemia in Hemodialysis Patients in Saudi Arabia
by: Shaheen Faissal, et al.
Published: (2006-01-01)

Neuroprotective effects of erythropoietin on neurodegenerative and ischemic brain diseases: the role of erythropoietin receptor
by: Carolina Castillo Hernández, et al.
Published: (2017-01-01)

Erythropoietin and Cancer: The Unintended Consequences of Anemia Correction
by: Nataša eDebeljak, et al.
Published: (2014-11-01)

Erythropoietin Promotes Infection Resolution and Lowers Antibiotic Requirements in E. coli- and S. aureus-Initiated Infections
by: Feihong Liang, et al.
Published: (2021-04-01)

Second-generation non-hematopoietic erythropoietin-derived peptide for neuroprotection
by: Bongki Cho, et al.
Published: (2022-02-01)

APPLICATION OF ERYTHROPOIETIN THETA IN THERAPY OF ANEMIA IN ONCOLOGIC PATIENTS
by: O. A. GLADKOV, et al.
Published: (2016-12-01)

Expression of erythropoietin and its receptor increases in colonic neoplastic progression: The role of hypoxia in tumorigenesis
by: Zoltan Gombos, et al.
Published: (2011-01-01)

Erythropoietin promoted the proliferation of hepatocellular carcinoma through hypoxia induced translocation of its specific receptor
by: Shuo Miao, et al.
Published: (2017-12-01)

Erythropoietin resistance in patients with regular hemodialysis in Sohag university hospital
by: Nagwa S. Ahmed, et al.
Published: (2023-06-01)

Potential effective treatment of shortening continuous erythropoietin receptor activator treatment interval combined with iron supplementation in hemodialysis patients
by: Yuki Kawai, et al.
Published: (2021-09-01)

The Many Facets of Erythropoietin Physiologic and Metabolic Response
by: Sukanya Suresh, et al.
Published: (2020-01-01)

The relationship between the dose of continuous erythropoietin receptor activator and oxidative stress in hemodialysis patients
by: N. Stepanova, et al.
Published: (2018-09-01)

Erythropoietin Non-hematopoietic Tissue Response and Regulation of Metabolism During Diet Induced Obesity
by: Soumyadeep Dey, et al.
Published: (2021-09-01)

Efficacy, tolerability and safety of darbepoetin alfa injection for the treatment of anemia associated with chronic kidney disease (CKD) undergoing dialysis: a randomized, phase-III trial
by: Shubhadeep D. Sinha, et al.
Published: (2019-03-01)

Erythropoietin Potentiates the Anti-proliferative Effect of Tamoxifen in Ovarian Adenocarcinoma A2780 Cells
by: Patrícia Kimáková, et al.
Published: (2018-12-01)

Erythropoietin Receptor (EPOR) Signaling in the Osteoclast Lineage Contributes to EPO-Induced Bone Loss in Mice
by: Zamzam Awida, et al.
Published: (2022-10-01)

Effect of recombinant human erythropoietin and its combination with tamoxifen on viability of MCF-7 cell in three-dimensional culture
by: Shujaaedin, Hareth Yahya Ahmed
Published: (2019)

Erythropoietin: function and therapeutic potential
by: A. P. Lykov
Published: (2023-04-01)

Association between Anti-Erythropoietin Receptor Antibodies and Cardiac Function in Patients on Hemodialysis: A Multicenter Cross-Sectional Study
by: Yasuhiro Mochida, et al.
Published: (2022-08-01)

Darbepoetin alfa injection versus epoetin alfa injection for treating anemia of Chinese hemodialysis patients with chronic kidney failure: A randomized, open‐label, parallel‐group, non‐inferiority Phase III trail
by: Nan Chen, et al.
Published: (2022-03-01)

LONG-ACTING ERYTHROPOETIN EFFICACY IN THE TREATMENT OF NEPHROGENIC ANEMIA IN PATIENTS WITH CHRONIC KIDNEY DISEASE AT A PREDIALYSIS STAGE
by: Yu S Milovanov, et al.
Published: (2012-06-01)

Resistance of dialyzed patients to erythropoietin
by: Michelle Teodoro Alves, et al.
Published: (2015-06-01)

"EFFECT OF HIGH VERSUS LOW DOSES OF HUMAN RECOMBINANT ERYTHROPOIETIN ON THE ANEMIA OF PREMATURITY"
by: A. Mohammadzadeh, et al.
Published: (2005-04-01)

Gamma-Aminobutyric Acid Increases Erythropoietin by Activation of Citrate Cycle and Stimulation of Hypoxia-Inducible Factors Expression in Rats
by: Keun-Tae Park, et al.
Published: (2020-04-01)

CLINICAL AND ECONOMIC ANALYSIS OF USING OF LONG ACTION ERYTHROPOES STIMULATED AGENTS FOR THE TREATMENT OF ANEMIA CKD V HD PATIENTS
by: M. Kolesnyk, et al.
Published: (2015-08-01)

Renal Cell Protection of Erythropoietin beyond Correcting The Anemia in Chronic Kidney Disease Patients
by: Hamid Nasri
Published: (2013-01-01)

Asialo-rhuEPO as a Potential Neuroprotectant for Ischemic Stroke Treatment
by: Farooqahmed S. Kittur, et al.
Published: (2023-04-01)

The Recombinant Human Erythropoietin Administered in Neonatal Rats After Excitotoxic Damage Induces Molecular Changes in the Hippocampus
by: Martha Catalina Rivera-Cervantes, et al.
Published: (2019-02-01)

Polycythemia caused by erythropoietin‐producing hemangiosarcoma
by: Osamu Imataki, et al.
Published: (2024-02-01)

Resistance to recombinant human erythropoietin therapy in haemodialysis patients
by: Elísio Costa, et al.
Published: (2009-06-01)

Pharmacoeconomic analysis of long term use of darbepoetin-α in treating chronic nephropathy-induced anemia in dialysed patients
by: Nicola Giotta, et al.
Published: (2007-06-01)

A Review of Pleiotropic Potential of Erythropoietin as an Adjunctive Therapy for COVID-19
by: Fatemeh EmamiPari, et al.
Published: (2022-02-01)

Study the relationship of erythropoietin and chronic obstructive pulmonary disease
by: R.I. El-Korashy, et al.
Published: (2012-07-01)